Author/Authors :
Ahmed, Kamran A. Department of Radiation Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Daniel Grass, G Department of Radiation Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Orman, Amber G. Department of Radiation Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Liveringhouse, Casey University of South Florida College of Medicine - Tampa - FL 33612, USA , Montejo, Michael E. Department of Radiation Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Soliman, Hatem H. Department of Breast Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Han, Heather S. Department of Breast Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Czerniecki, Brian J. Department of Breast Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Torres-Roca, Javier F. Department of Radiation Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA , Diaz, Roberto Department of Radiation Oncology - H. Lee Moftt Cancer Center and Research Institute - Tampa - FL 33612, USA
Abstract :
Long-term data establishes the efcacy of radiotherapy in the adjuvant management of breast cancer. New dose and fractionation
schemas have evolved and are available, each with unique risks and rewards. Current eforts are ongoing to tailor radiotherapy to
the unique biology of breast cancer. In this review, we discuss our eforts to personalize radiotherapy dosing using genomic data and
the implications for future clinical trials. We also explore immune mechanisms that may contribute to a tumor’s unique radiation
sensitivity or resistance.
